ALPHA IVF GROUP BERHAD
KLSE (MYR): ALPHA (0303)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.33
Today's Change
+0.005 (1.54%)
Day's Change
0.32 - 0.33
Trading Volume
21,607,900
Post a Comment
Market Buzz
2024-05-17
2024-05-17
2024-05-16
Featured Posts
Apps
Top Articles
1
AnimatedMotion
2
The Alpha Trader
3
4
THE INVESTMENT APPROACH OF CALVIN TAN
5
AmInvest Research Reports
6
BFM Podcast
7
BFM Podcast
8
BFM Podcast
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
ronnie2u
661 posts
Posted by ronnie2u > 2 months ago | Report Abuse
From LinkedIn:
The Dragon Amongst ACE Market IPO - Alpha IVF
Entering 2024, Alpha IVF Group Berhad is emerging as a noteworthy company, poised to make its debut on the stock market. This development is not just another IPO; it signifies the entry of Malaysia’s second company, after another listed on the LEAP market, to specialize in assisted reproductive services. With a focus on providing hope to couples facing infertility challenges, Alpha IVF stands out for its advanced in vitro fertilization (IVF) and other reproductive technologies.
Rumors suggest that Alpha IVF’s post-IPO valuation could fetch over RM1.0 billion, potentially marking it as one of the largest IPOs in the ACE market segment in recent years. Such anticipation is fueled by the company’s impressive financial performance, with Profit After Tax (PAT) margins showing substantial growth over recent fiscal periods, highlighting the company’s operational efficiency and profitability.
Alpha IVF’s financial resilience is evident from its escalating PAT margins, which have outperformed many in the tech sector. With figures rising from 3.71% in FYE2021 to an astonishing 43.59% in FPE2023 (9 months), the company’s profitability trajectory is impressive. However, the sustainability of these margins remains a focal point of interest as the official prospectus is awaited, with many fund managers keenly observing.
Post-IPO, Alpha IVF intends to uphold a generous dividend payout ratio of 60.0%, promising a substantial return to its shareholders. This strategy underscores the company’s confidence in its cash-generative business model, which relies more on expertise than on heavy asset investments. Furthermore, Alpha IVF’s expansion plans include extending its footprint to Indonesia and potentially Cambodia or Laos, alongside establishing a sales center in China to tap into the burgeoning medical tourism sector.
At the heart of Alpha IVF’s success is its comprehensive approach to understanding and addressing the unique needs of its clients. From assessing sperm and ova health to pioneering techniques in ovarian stimulation and cryopreservation, the company stands at the forefront of reproductive technology. Alpha IVF’s services extend beyond traditional IVF, incorporating advanced procedures like Preimplantation Genetic Testing (PGT) to enhance success rates and reduce genetic risks.
In an era where technology intersects with healthcare, Alpha IVF leverages AI to select embryos with higher chances of successful implantation, further refining its service offerings. The company also explores innovative treatments like Ova-PRP to improve ovarian health, showcasing its commitment to advancing reproductive technologies.
With declining birth rates and changing societal attitudes towards parenthood, IVF services like those offered by Alpha IVF may become increasingly sought after, presenting a compelling narrative for investors and industry observers alike.